[
    [
        {
            "time": "2018-09-15",
            "original_text": "Large Cap Pharma Stocks Staging a Comeback in Second Half",
            "features": {
                "keywords": [
                    "Large Cap",
                    "Pharma",
                    "Comeback",
                    "Second Half"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 10,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-03",
            "original_text": "Recent Product Approvals Bode Well for Intuitive Surgical",
            "features": {
                "keywords": [
                    "Product Approvals",
                    "Intuitive Surgical"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-10-10",
            "original_text": "Analyzing Intuitive Surgical’s Operational Performance",
            "features": {
                "keywords": [
                    "Intuitive Surgical",
                    "Operational Performance"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-15",
            "original_text": "What Alexion Pharmaceuticals’ Valuation Trend Indicates",
            "features": {
                "keywords": [
                    "Alexion Pharmaceuticals",
                    "Valuation Trend"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-20",
            "original_text": "Johnson & Johnson To Present At Barclays Conference; Webcast At 12:45 PM ET",
            "features": {
                "keywords": [
                    "Johnson & Johnson",
                    "Barclays Conference",
                    "Webcast"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 6,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-10-25",
            "original_text": "Johnson & Johnson To Present At Wells Fargo Conference; Webcast At 9:45 AM ET",
            "features": {
                "keywords": [
                    "Johnson & Johnson",
                    "Wells Fargo Conference",
                    "Webcast"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 6,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-11-01",
            "original_text": "J&J Submits NDA to the FDA for Depression Drug in Adults",
            "features": {
                "keywords": [
                    "J&J",
                    "NDA",
                    "FDA",
                    "Depression Drug"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]